Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for HCA and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HCA and 80,000+ other tickers.
See exactly how HCA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HCA and 80,000+ other tickers.
HCA Healthcare, Inc., operating through its subsidiaries, delivers a comprehensive array of healthcare services throughout the United States. The organization manages a network of general and acute care hospitals that provide a full spectrum of medical and surgical care, encompassing inpatient services, intensive care, cardiac treatment, diagnostic procedures, and emergency services. These hospitals additionally offer a broad range of outpatient care, such as ambulatory surgery, laboratory testing, radiology, respiratory therapy, cardiology, and physical therapy. Beyond its hospital…
AlphaGrep UK Ltd acquired a new stake in shares of HCA Healthcare, Inc. (NYSE: HCA) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,767 shares of the company's stock, valued at approximately $1,079,000. A number of other hedge funds and other institutional
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA).
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
HCA Healthcare's resiliency program is helping control costs amid payer pressures, potentially supporting long-term profitability and EBITDA growth.
On August 25, 2026, we conducted a DCF analysis for HCA Healthcare Inc (HCA), a company that has shown varied price performance recently. The stock has experien